Study: 95% of ODs in children under 5 were self-ingested
CINCINNATI — The vast majority of pharmaceutical overdoses in children that resulted in a trip to the emergency room resulted from self-ingestion, according to a study released Friday.
"We need to know the medications and ingestion circumstances that contribute most to [emergency room] visits, hospitalization and harm," stated Randall Bond, lead researcher. The authors found that 95% of ER visits resulted from self-ingestion. Prescription drugs accounted for 55% of the ER visits, 76% of hospital admissions and 71% of significant injuries. The biggest impact came from opioid-containing pain medications (e.g., oxycodone, morphine and codeine), sedative hypnotics (e.g., muscle relaxants and sleep aids) and cardiovascular medications.
"The problem of pediatric poisoning in the U.S. is getting worse, not better," Bond said. Overall, there was a 22% increase in the exposure for this age group, although the number of children in the United States under the age of 5 years increased only 8% during the study period.
The authors attributed this increase to a greater availability of, and access to, medications in the child’s home. "Prevention efforts of parents and caregivers to store medicines in locked cabinets or up and away from children continue to be crucial. However, the largest potential benefit would come from packaging design changes that reduce the quantity a child could quickly and easily access in a self-ingestion episode, like flow restrictors on liquids and one-at-a-time tablet dispensing containers," Bond suggested. He recommended such changes should be applied to both adult and pediatric products and to over-the-counter and prescription products.
Bond and colleagues from Cincinnati Children’s Hospital Medical Center and the University of Cincinnati gathered information about 544,133 children 5 years of age and younger who had visited the emergency department because they may have been poisoned by medication. The data was gathered from all cases reported to the American Association of Poison Control Centers between 2001 and 2008. In an attempt to find a focus for continued poison prevention methods, the authors organized the data according to medication type and whether the exposure was caused by the child self-ingesting the medication or by a dosing error.
The new study will soon be published in The Journal of Pediatrics.
BMS, AstraZeneca drug added to insulin reduces blood sugar more than placebo
PRINCETON, N.J. — A diabetes drug made by Bristol-Myers Squibb and AstraZeneca significantly reduced Type 2 diabetes patients’ blood-sugar levels, compared with placebo, when added to insulin, according to results of a new study.
The two companies presented results of a 24-week extension to a 52-week study of Onglyza (saxagliptin) at the European Association for the Study of Diabetes’ 47th annual meeting in Lisbon, Portugal; they had presented results from the original study at the American Diabetes Association’s scientific sessions in San Diego in June.
The phase-3b study found that patients taking 5 mg of Onglyza with insulin had a 0.75% reduction in HbA1C, compared with 0.38% of those taking insulin and placebo.
Walgreens, ESI dispute moves to arbitration following court decision
CHICAGO — U.S. District Court judge Marvin Aspen ruled in favor of Walgreens on Thursday; Express Scripts’ federal suit against Walgreens will be halted pending arbitration.
The Express Scripts charges against Walgreens of breach of contract now will move to arbitration. Express Scripts originally had objected to arbitration because the process would be too slow. However, there may be some sense of urgency as Judge Aspen scheduled a status hearing for Dec. 8.
"We are very pleased with the court’s decision today, in which Judge Aspen agreed that Express Scripts brought its claims in the wrong forum, granted our motion and ordered Express Scripts to abide by its contractual obligations and submit the matter to binding arbitration," Walgreens spokesman Michael Polzin said.
Express Scripts also was satisfied with the ruling. "We are pleased the court recognized the importance of getting this decided quickly," Thom Gross, Express Scripts senior manager communications, shared with Drug Store News in an email. "The court effectively said delay is not an option. We are perfectly happy to go to arbitration — we just want a quick resolution," he noted. "We will continue to pursue injunctive relief either in arbitration or in federal court."